EMPAGLIFLOZIN
Total Payments
$321,274
Transactions
40
Doctors
18
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $27,079 | 3 | 1 |
| 2018 | $74,032 | 11 | 3 |
| 2017 | $220,163 | 26 | 14 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $156,863 | 16 | 48.8% |
| Consulting Fee | $81,638 | 10 | 25.4% |
| Unspecified | $64,146 | 6 | 20.0% |
| Travel and Lodging | $18,627 | 8 | 5.8% |
Payments by Type
General
$257,128
34 transactions
Research
$64,146
6 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Empagliflozin and Heart failure (HFrEF) | Boehringer Ingelheim Pharma GmbH & Co.KG | $64,146 | 0 |
Top Doctors Receiving Payments for EMPAGLIFLOZIN
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Saint Louis, MO | $126,240 | 14 |
| , M.D | Internal Medicine | San Francisco, CA | $27,079 | 3 |
| , M.D | Endocrinology, Diabetes & Metabolism | Little Rock, AR | $24,927 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Dallas, TX | $22,539 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Tupelo, MS | $20,889 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Aurora, CO | $20,847 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Buffalo, NY | $11,727 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Buffalo, NY | $11,727 | 1 |
| , DO | Cardiovascular Disease | San Antonio, TX | $11,546 | 2 |
| Rajeev Jain | — | Milwaukee, WI | $10,880 | 1 |
| , MD | Internal Medicine | Hyattsville, MD | $10,445 | 1 |
| , MD | Advanced Heart Failure and Transplant Cardiology | Columbus, OH | $9,892 | 1 |
| , M.D | Specialist | New Orleans, LA | $7,022 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | New Haven, CT | $2,000 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Orlando, FL | $1,157 | 2 |
| , MD | Geriatric Medicine | Orlando, FL | $1,157 | 2 |
| , M.D | Endocrinology, Diabetes & Metabolism | Atlanta, GA | $904.19 | 4 |
| , MD | Pediatric Endocrinology | New Haven, CT | $250.00 | 1 |
| , MD | Advanced Heart Failure and Transplant Cardiology | Nashville, TN | $46.00 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $321,274
- Total Doctors 18
- Transactions 40
About EMPAGLIFLOZIN
EMPAGLIFLOZIN is a drug associated with $321,274 in payments to 18 healthcare providers, recorded across 40 transactions in the CMS Open Payments database. The primary manufacturer is Boehringer Ingelheim Pharmaceuticals, Inc..
Payment data is available from 2017 to 2019. In 2019, $27,079 was paid across 3 transactions to 1 doctors.
The most common payment nature for EMPAGLIFLOZIN is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($156,863, 48.8% of total).
EMPAGLIFLOZIN is associated with 1 research study, including "Empagliflozin and Heart failure (HFrEF)" ($64,146).